[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ad18fb923edfd75560344b1d12ed86a07e4e8bb7948de457886e56d318ca9c35",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760027640,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 137078233,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ad18fb923edfd75560344b1d12ed86a07e4e8bb7948de457886e56d318ca9c35"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
    "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
    "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760016130,
      "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
      "id": 137032881,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193052383/image_1193052383.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
      "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8"
    }
  },
  {
    "ts": null,
    "headline": "Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer",
    "summary": "Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysisOver 100 clinical sites across 24 countries now activated and open for recruitment Futility analysis remains on track for completion in the first quarter of CY2026 SYDNEY, AUSTRALIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targetin",
    "url": "https://finnhub.io/api/news?id=8d659357730853458dd952c32d0980b7c4124414cef55844c9a14fd40573e957",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760011200,
      "headline": "Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer",
      "id": 137031246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysisOver 100 clinical sites across 24 countries now activated and open for recruitment Futility analysis remains on track for completion in the first quarter of CY2026 SYDNEY, AUSTRALIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targetin",
      "url": "https://finnhub.io/api/news?id=8d659357730853458dd952c32d0980b7c4124414cef55844c9a14fd40573e957"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025",
    "summary": "RAHWAY, N.J., October 09, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place Oct.15-18, 2025, in Paris, France. The company’s presentations will include:",
    "url": "https://finnhub.io/api/news?id=08abbfb7b2608c41dcc1536899d16db9d53242cc8623b64a4464933ee9f9c9e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760007600,
      "headline": "Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025",
      "id": 137031247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 09, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place Oct.15-18, 2025, in Paris, France. The company’s presentations will include:",
      "url": "https://finnhub.io/api/news?id=08abbfb7b2608c41dcc1536899d16db9d53242cc8623b64a4464933ee9f9c9e6"
    }
  },
  {
    "ts": null,
    "headline": "Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025",
    "summary": "RAHWAY, N.J., October 09, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across more than 20 types of cancer and multiple treatment settings from the company’s broad and differentiated portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, from Oct. 17-21. These data showcase Merck’s commitment to rapidly advancing research across multi",
    "url": "https://finnhub.io/api/news?id=6e96d0965fe076865fe94b6e0b70829b90a098fac9394239f8d33ccce0446017",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760006700,
      "headline": "Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025",
      "id": 137031248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 09, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across more than 20 types of cancer and multiple treatment settings from the company’s broad and differentiated portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, from Oct. 17-21. These data showcase Merck’s commitment to rapidly advancing research across multi",
      "url": "https://finnhub.io/api/news?id=6e96d0965fe076865fe94b6e0b70829b90a098fac9394239f8d33ccce0446017"
    }
  },
  {
    "ts": null,
    "headline": "Merck will highlight its progress in oncology at the ESMO 2025 Congress",
    "summary": "Merck announces the presentation of over 100 studies covering more than 20 types of cancer at the European Society for Medical Oncology 2025 Congress, to be held in Berlin from October 17 to 21. Two...",
    "url": "https://finnhub.io/api/news?id=66833f5bed3dbc7673ca819325792c3c3e0fa0b7f64088f82856ba5235ac6905",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760001033,
      "headline": "Merck will highlight its progress in oncology at the ESMO 2025 Congress",
      "id": 137031924,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces the presentation of over 100 studies covering more than 20 types of cancer at the European Society for Medical Oncology 2025 Congress, to be held in Berlin from October 17 to 21. Two...",
      "url": "https://finnhub.io/api/news?id=66833f5bed3dbc7673ca819325792c3c3e0fa0b7f64088f82856ba5235ac6905"
    }
  },
  {
    "ts": null,
    "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
    "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
    "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759998180,
      "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
      "id": 137029703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
      "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4"
    }
  }
]